Premium
P2‐237: Novel 18F‐labeled quinoline derivatives for in vivo detection of tau pathology in Alzheimer's disease
Author(s) -
Okamura Nobuyuki,
Furumoto Shozo,
Harada Ryuichi,
FoderoTavoletti Michelle,
Villemagne Victor,
Iwata Ren,
Yanai Kazuhiko,
Kudo Yukitsuka
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.944
Subject(s) - biodistribution , chemistry , hippocampal formation , fibril , in vivo , genetically modified mouse , senile plaques , amyloid (mycology) , imaging agent , alzheimer's disease , pathology , biophysics , biochemistry , neuroscience , transgene , medicine , in vitro , biology , disease , inorganic chemistry , microbiology and biotechnology , gene
thickness was predictive of increasing apathy over time (P <0.0001; R 2 1⁄4 0.59 for full model with random and fixed terms), while reduced supramarginal cortical thickness was predictive of increasing hallucinations over time (P 1⁄4 0.04; R 2 1⁄4 0.66 for model). There was no association with cortical thickness cross-sectionally. CSF biomarkers were not related to apathy or hallucinations severity in cross-sectional or longitudinal analyses. Conclusions: These results suggest that temporal and parietal cortical thinning is associated with worsening apathy and hallucinations in a large cohort across the AD spectrum.CSFADbiomarkers did not show associationswith these neuropsychiatric symptoms. Additional longitudinal studies may further elucidate the expression and time course of these debilitating symptoms in relation to AD biomarkers.